Breast Cancer PSMA PET

Launched by AHMAD SHARIFTABRIZI · Sep 3, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a specific aspect of metastatic Triple Negative Breast Cancer (TNBC), which is a type of breast cancer that can spread to other parts of the body. The researchers want to see how a certain marker called Prostate Specific Membrane Antigen (PSMA) shows up in patients with this cancer using a special imaging technique called FDG PET/CT. They believe that many of the cancer spots in these patients will show this marker, which could lead to new treatment options using PSMA-targeted therapies. The study plans to enroll 30 women who have been diagnosed with metastatic TNBC, and they will be part of the study for up to four weeks.

To be eligible to join the trial, participants must be women at least 18 years old with confirmed metastatic TNBC and must have had a positive PET/CT scan showing cancer spread. However, women who have other active cancers, cannot have the PET/CT scan, are pregnant or breastfeeding, or have certain medical conditions that could make the procedure unsafe cannot participate. If you join this study, you can expect to undergo imaging tests to help the researchers gather important information about your condition and potential treatment options.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female \>= 18 years of age
• • Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
• • Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.
• Exclusion Criteria:
• • Patients with known active other malignancy.
• • Unable to tolerate PET/CT procedure.
• • Pregnant or breastfeeding.
• • Patients with any medical condition that might compromise the safety of subject during PET acquisitions.